![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Purpose: To assess the effects of tranilast on degranulation and IL-13 production in mast cells activated by IL-33 and cross-linking of FcɛRI.
Methods: Bone marrow-derived mast cells (BMMCs) were sensitized with anti-DNP IgE. Sensitized cells were pretreated with tranilast and further stimulated with DNP-BSA, IL-33, or a combination of DNP-BSA and IL-33. Degranulation and the level of IL-13 release and mRNA expression in BMMCs were measured.
Results: Simultaneous stimulation with DNP-BSA and IL-33 resulted in marked increase in β-hexosaminidase release. Tranilast significantly inhibited degranulation of BMMCs in the condition of combined treatment of DNP-BSA and IL-33. Combination of DNP-BSA and IL-33 induced a pronounced increase in the IL-13 release and mRNA expression. Tranilast significantly inhibited IL-13 release and mRNA expression in BMMCs stimulated by DNP-BSA and IL-33.
Conclusions: Tranilast has efficacy on the inhibition of degranulation and IL-13 production in BMMCs induced by the combination of DNP-BSA and IL-33.
FUNDING
Kazuhiro Tsuji received employment income and Atsuki Fukushima received research funding from Rohto Pharmaceutical Co. Ltd. Ken Fukuda has no conflict of interest to declare.